Assignment history

Inventors

• David Townley (Neurent Medical Ltd)

Original assignee

The original assignee, Neurent Medical Ltd, is a medical device company focused on treating chronic inflammatory diseases of the nose. They ship a product called the NEUROMARK System, which embodies the claims of this patent for therapeutic nasal treatment. Neurent Medical Ltd is currently operating.

Assignment timeline

• 2024-06-25 (executed) / recorded 2024-06-25 — Reel 006249/0513

  • Conveyance: Assignment of Assignors Interest
  • Assignor: TOWNLEY, David
  • Assignee: Neurent Medical Limited
  • Correspondent: GORDON E. NELSON, ESQ., 500 George Washington Highway, Smithfield, RI 02917. This correspondent also appears on other patent assignments.
  • Context: Internal reorg (assignment from inventor to company)

• 2024-10-18 (executed) / recorded 2024-10-18 — Reel 006282/0268

  • Conveyance: Security Interest
  • Assignor: Neurent Medical Limited
  • Assignee: CLARET EUROPEAN SPECIALTY LENDING COMPANY III, S.A R.L.
  • Correspondent: K&L GATES LLP, C/O CPA GLOBAL, 1334 G STREET NW, WASHINGTON, DC 20005.
  • Context: Securitization

Timeline diagram

timeline
    title Ownership of US 12096974
    2024 : Inventor assigned to Neurent Medical
         : Neurent Medical assigned to Claret European

NPE / troll-pattern signals

1. Shell-entity transfer — not present. The initial assignment is from the inventor to an operating company (Neurent Medical Limited), and the subsequent transfer is a security interest to a lending company.
2. Known asserter in the chain — not present. Neither Neurent Medical Limited nor Claret European Specialty Lending Company III, S.A R.L. appear on public NPE lists.
3. Repeat correspondent across the chain — unclear. GORDON E. NELSON, ESQ. is noted as appearing on other patent assignments, but without further context on which assignments, it's not a strong signal for this specific chain. K&L GATES LLP appears once.
4. Cascading transfers — not present. There are two assignments recorded, but they are not consecutive transfers through chained LLCs in a short timeframe that would indicate a cascading pattern.
5. Pre-litigation transfer — unclear. The patent was granted on 2024-09-24. While litigation has been filed (a US case in Delaware District Court and a PTAB case IPR2025-01127), the exact filing dates of these cases relative to the assignment dates are not specified in the provided patent text, beyond the fact that the application was filed by Neurent Medical Ltd on 2024-04-26.
6. Bankruptcy fire-sale — not present. No indication of bankruptcy for Neurent Medical Ltd.
7. Privateering — not present. No evidence in the assignment records or provided text to suggest privateering.
8. Defensive aggregator (anti-NPE) — not present. The chain does not end at a known defensive aggregator.

Verdict

Operating-company assertion
The initial assignment is from the inventor to Neurent Medical Limited, an operating company that markets a product embodying the patent claims. The subsequent assignment is a security interest to a lending company, which is typical for an operating business. There are no clear signals of transfers to shell entities or known NPEs.
https://assignmentcenter.uspto.gov/patent/index.html